Equities analysts expect Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings of $0.72 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.76 and the lowest estimate coming in at $0.67. Eagle Pharmaceuticals reported earnings of $0.84 per share in the same quarter last year, which would indicate a negative year over year growth rate of 14.3%. The company is expected to report its next earnings results on Monday, May 10th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $3.25 per share for the current financial year, with EPS estimates ranging from $3.08 to $3.41. For the next year, analysts forecast that the company will report earnings of $3.62 per share, with EPS estimates ranging from $2.62 to $4.62. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Monday, March 1st. The specialty pharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of ($1.42) by $2.38. Eagle Pharmaceuticals had a return on equity of 8.50% and a net margin of 2.65%.
Separately, Zacks Investment Research raised Eagle Pharmaceuticals from a “sell” rating to a “buy” rating and set a $48.00 price objective for the company in a research report on Monday, March 8th.
Several large investors have recently added to or reduced their stakes in EGRX. Norges Bank bought a new stake in Eagle Pharmaceuticals in the fourth quarter valued at about $8,018,000. Park West Asset Management LLC grew its holdings in Eagle Pharmaceuticals by 24.4% in the 4th quarter. Park West Asset Management LLC now owns 791,600 shares of the specialty pharmaceutical company’s stock worth $36,865,000 after buying an additional 155,062 shares in the last quarter. Morgan Stanley lifted its position in Eagle Pharmaceuticals by 226.6% in the third quarter. Morgan Stanley now owns 166,829 shares of the specialty pharmaceutical company’s stock worth $7,087,000 after purchasing an additional 115,747 shares during the period. Brandes Investment Partners LP lifted its position in Eagle Pharmaceuticals by 70.7% in the fourth quarter. Brandes Investment Partners LP now owns 264,397 shares of the specialty pharmaceutical company’s stock worth $12,295,000 after purchasing an additional 109,473 shares during the period. Finally, Matarin Capital Management LLC acquired a new stake in Eagle Pharmaceuticals in the third quarter worth approximately $2,018,000. Institutional investors and hedge funds own 95.12% of the company’s stock.
Eagle Pharmaceuticals stock traded up $0.18 during mid-day trading on Thursday, hitting $39.81. 1,225 shares of the company were exchanged, compared to its average volume of 122,106. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.60 and a quick ratio of 3.45. The business’s 50 day simple moving average is $43.82 and its two-hundred day simple moving average is $46.14. The company has a market capitalization of $526.17 million, a P/E ratio of 113.03 and a beta of 0.74. Eagle Pharmaceuticals has a 12-month low of $36.48 and a 12-month high of $56.16.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Featured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?
Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com